Aim: To evaluate the role of intravitreal Triamcinolone (TA) in the early management of Coats’ disease.
Methods: Prospective, interventional case series.
Results: Fifteen consecutive cases with Coats’ disease were managed with 4mg/0.1ml intravitreal Triamcinolone injection on presentation and were followed for a minimum of one year duration. Additional management strategies including drainage of subretinal fluid through an inferior sclerotomy, peripheral laser ablation and/or cryotherapy, cataract extraction, and vitrectomy were performed. Improvement of visual acuity could be achieved compared to preoperative vision in all cases in this series even when 40% needed cataract extraction with intra ocular lens implantation. One patient needed anti glaucoma treatment to control raised intraocular pressure in this series.
Conclusion: Triamcinolone has a role in improving the rate of absorption of subretinal fluid and macular exudates in Coats’ disease. Major complication of 4mg/0.1 ml intravitreal triamcinolone is cataract in 40 % of cases in children.